DiaSorin SpA (DiaSorin) is a medical devices company focused on developing, manufacturing and marketing of immunodiagnostic and molecular diagnostic reagent kits and systems. The company offers in vitro diagnostic products for various clinical segments including infectious diseases, endocrinology, bone metabolism, hypertension, autoimmunity, oncology among others. It offers its products to hospitals and private testing laboratories. DiaSorin has presence in around 106 countries worldwide.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

DiaSorin conducts research to advance diagnostic kits for the infectious disease market and assays that are run on the DAD (Direct Amplification Disc) disk and do not need nucleic acids extraction. It also focuses on expanding tests array available on the Liaison product line. It is currently conducting R&D activities targeted towards molecular platforms for direct identification of pathogens to immunodiagnostics, and immune response biomarkers. It is also developing latest applications of the diagnostic algorithms and the artificial intelligence for the differential diagnosis and assessment of severity and prognosis of the disease. In FY2022, the company spent EUR78.7 million on its R&D activities, which amounted to 5.8% of the company’s annual revenue. DiaSorin operates nine research facilities in the world, including seven research facilities in the US, and two in Italy.